How to buy Viatris stock

Viatris Inc is a drug manufacturers-specialty & generic business based in the US. Viatris shares (MYL) are listed on the NASDAQ and all prices are listed in US Dollars. Viatris employs 35,000 staff and has a trailing 12-month revenue of around 0.00.

Viatris stock price (NASDAQ: MYL)

Use our graph to track the performance of MYL stocks over time.

Viatris shares at a glance

• Key figures

Information last updated 2021-01-17.

52-week range	$0.08 - $17.69
50-day moving average	$16.42
200-day moving average	$16.12
Wall St. target price	$21.75
PE ratio	30.7267
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.52

Buy Viatris shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Viatris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Viatris Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Viatris under- or over-valued?

Valuing Viatris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Viatris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Viatris's P/E ratio

Viatris's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Viatris shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Viatris's PEG ratio

Viatris's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Viatris's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Viatris's EBITDA

Viatris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.5 billion.

The EBITDA is a measure of a Viatris's overall financial performance and is widely used to measure a its profitability.

Viatris financials

Revenue TTM	$11.5 billion
Operating margin TTM	15.72%
Gross profit TTM	$4.6 billion
Return on assets TTM	3.63%
Return on equity TTM	0%
Profit margin	2.31%
Book value	$24.27
Market capitalisation	$8.6 billion

TTM: trailing 12 months

Shorting Viatris shares

There are currently 47.1 million Viatris shares held short by investors – that's known as Viatris's "short interest". This figure is 1.4% up from 46.5 million last month.

There are a few different ways that this level of interest in shorting Viatris shares can be evaluated.

Viatris's "short interest ratio" (SIR)

Viatris's "short interest ratio" (SIR) is the quantity of Viatris shares currently shorted divided by the average quantity of Viatris shares traded daily (recently around 4.2 million). Viatris's SIR currently stands at 11.15. In other words for every 100,000 Viatris shares traded daily on the market, roughly 11150 shares are currently held short.

However Viatris's short interest can also be evaluated against the total number of Viatris shares, or, against the total number of tradable Viatris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viatris's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Viatris shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Viatris shares, roughly 111 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Viatris.

Find out more about how you can short Viatris stock.

Viatris's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Viatris.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Viatris's total ESG risk score

Total ESG risk: 37.23

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Viatris's overall score of 37.23 (as at 12/31/2018) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Viatris is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Viatris's environmental score

Environmental score: 1.95/100

Viatris's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Viatris's social score

Social score: 20.21/100

Viatris's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Viatris's governance score

Governance score: 14.07/100

Viatris's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Viatris is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Viatris's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Viatris scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Viatris has a damaged public profile.

Environmental, social, and governance (ESG) summary

Viatris Inc was last rated for ESG on: 2019-01-01.

Total ESG score	37.23
Total ESG percentile	77.8
Environmental score	1.95
Environmental score percentile	2
Social score	20.21
Social score percentile	2
Governance score	14.07
Governance score percentile	2
Level of controversy	4

Viatris share dividends

We're not expecting Viatris to pay a dividend over the next 12 months.

Have Viatris's shares ever split?

Viatris's shares were split on a 3:2 basis on 8 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Viatris shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Viatris shares which in turn could have impacted Viatris's share price.

Viatris share price volatility

Over the last 12 months, Viatris's shares have ranged in value from as little as $0.077 up to $17.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viatris's is 1.4656. This would suggest that Viatris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viatris overview

Mylan N. V. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.

Frequently asked questions

What percentage of Viatris is owned by insiders or institutions?
Currently 0.912% of Viatris shares are held by insiders and 90.496% by institutions. How many people work for Viatris?
Latest data suggests 35,000 work at Viatris. When does the fiscal year end for Viatris?
Viatris's fiscal year ends in December. Where is Viatris based?
Viatris's address is: Building 4, Hatfield, United Kingdom, AL10 9UL What is Viatris's ISIN number?
Viatris's international securities identification number is: NL0011031208 What is Viatris's CUSIP number?
Viatris's Committee on Uniform Securities Identification Procedures number is: 628530107